


# Association of Women Surgeons

5204 Fairmount Avenue, Suite 208, Downers Grove, IL 60515 • 630-655-0392 • Fax: 630-493-0798 • WomenSurgeons.org



## Association of Women Surgeons in partnership with Genomic Health

Presents a  
**Special Networking Breakfast Program**  
Tuesday, October 9, 2007  
7:00 – 9:00 a.m.  
InterContinental Hotel, New Orleans



Just  
Added  
New  
Program

### Schedule

|           |   |   |
|-----------|---|---|
| 7:00 a.m. | Complimentary Networking Breakfast          |   |
| 8:00 a.m. | "Oncotype DX Breast Cancer Tumor Board"     |   |
| 8:00      | Opening Remarks                             | Susan Pories, MD  |
| 8:05      | <i>The Promise of Personalized Medicine</i> | Susan Pories, MD  |
| 8:15      | Oncotype DX Overview                        | Rosemary Leeming, MD  |
| 8:30      | Oncotype DX Case Studies                    | Panel Discussion:<br>Susan Pories, MD<br>Rosemary Leeming, MD<br>Barb Schwartzberg, MD<br>Christine Laronga, MD |
| 8:50      | Questions and Answers                       |   |
| 9:00      | Adjourn                                     |   |

Since the sequencing of the Human Genome, personalized medicine has become a closer reality. The hope is that personalized medicine can help to achieve better outcomes and smarter treatments for a number of different diseases. One of the first areas in which significant progress has been made is in the treatment of early stage breast cancer. One of the first commercially available tests to aid treatment decisions in early stage breast cancer is the Oncotype DX assay. This assay measures the expression of 16 cancer-related genes to quantify a patient's risk of disease recurrence and indicate which patients may benefit from adjuvant chemotherapy. The test allows physicians and patients to make more individualized treatment decisions.

This program will provide an overview of personalized medicine, a summary of key data supporting the Oncotype DX assay, and an opportunity to discuss real patient cases and how treatment decisions are being impacted by the results of Oncotype DX. A recent multi-center study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that approximately 1/3 of adjuvant treatment decisions were changed based on Oncotype DX results.